← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
eIF2α Phosphorylation Imbalance Disrupts Mitochondrial Prote (EIF2S1,eIF2α,PERK,GCN2,ATF4,TOMM20,TIMM23,NDUFS1,NDUFS3,COX4I1,COX5A,mitochondrial protein import) — 0.00 TBK1 Loss Triggers Astrocyte-to-Neuron Senescence Propagatio (TBK1 → NF-κB / IRF3 / p62-autophagy / SASP effectors) — 0.00 TBK1 Loss Triggers eIF2α-Mediated Translational Repression T (TBK1, EIF2S1) — 0.00 GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Cl (GRIN2B) — 0.96 Closed-loop transcranial focused ultrasound targeting EC-II (SST) — 0.96 Closed-loop optogenetic targeting PV interneurons to restore (PVALB) — 0.95 Plasma NfL Elevation Secondary to BBB-Associated Transport D (NEFL) — 0.94 Closed-loop transcranial focused ultrasound to restore hippo (CCK) — 0.91 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming (NLRP3, CASP1, IL1B, PYCARD) — 0.91 Gamma entrainment therapy to restore hippocampal-cortical sy (SST) — 0.90 Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Colla (SLC16A1, SLC16A7, LDHA, PDHA1) — 0.89 SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc (SIRT1) — 0.89 TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegener (TREM2) — 0.89 Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Pa (APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis)) — 0.89 Optimized Temporal Window for Metabolic Boosting Therapy Det (IFNG) — 0.89 TREM2-APOE Axis Dissociation for Selective DAM Activation (TREM2-APOE axis) — 0.89 p38α Inhibitor and PRMT1 Activator Combination to Restore Ph (MAPK14/PRMT1) — 0.88 APOE-Dependent Autophagy Restoration (MTOR) — 0.88 Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 (BDNF) — 0.87 ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro (ACSL4) — 0.87 Complement Cascade Inhibition Synaptic Protection (%s) — 0.87 eIF2α Phosphorylation Imbalance Creates Integrated Stress Re (EIF2S1,eIF2α,PERK,GCN2,ATF4,ATF5,CHOP,DDIT3,integrated stress response,protein synthesis) — 0.87 Optogenetic restoration of hippocampal gamma oscillations vi (PVALB) — 0.87 Gamma Oscillation Entrainment Enhances lncRNA-9969-Mediated (PVALB, CREB1, lncRNA-9969, neuronal autophagy pathway) — 0.87 Glymphatic-Mediated Tau Clearance Dysfunction (MAPT) — 0.86 Closed-loop focused ultrasound targeting EC-II PV interneuro (PVALB) — 0.86 TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima (NAMPT) — 0.86 TREM2-Mediated Microglial Dysfunction Disrupts Perivascular (TREM2) — 0.86 Circadian Glymphatic Entrainment via Targeted Orexin Recepto (HCRTR1/HCRTR2) — 0.86 RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA P (RBM45,GSK3B,TDP-43,TARDBP,hnRNP A1,HNRNPA1,phase separation,Liquid droplet) — 0.86
Add
|
× Autophagy-Senescence Axis
ATG7,BCL2,BCL2L1 · - · therapeutic
Composite 0.624
Price $0.73
Evidence For 0
Evidence Against 0
## Mechanistic Overview
Autophagy-Senescence Axis Therapeutic Window starts from the claim that modulating ATG7,BCL2,BCL2L1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "# Autophagy-Senescence Axis Therapeutic Window: Sequential Targeting of ATG7 and BCL-2 Family Proteins in Neurodegeneration ## Background and Conceptual Framework The interplay between autophagy dysfunction and cellular senescence represents an emerging
Radar Chart — 10 Dimensions
Score Breakdown
Dimension Autophagy-Senescence Axis Ther Mechanistic 0.737 Evidence 0.700 Novelty 0.676 Feasibility 0.465 Impact 0.583 Druggability 0.700 Safety 0.700 Competition 0.600 Data 0.700 Reproducible 0.486 KG Connect 0.880
Evidence Autophagy-Senescence Axis Therapeutic Window No evidence citations yet
Price History Overlay
Knowledge Graph Comparison
Autophagy-Senescence Axis Therapeutic Wi
68 edges
Top Node Types gene 57
disease 6
drug 3
pathway 2
Top Relations co_discussed 54
investigated_in 7
activates 3
associated_with 2
contributes_to 1